Saturday 17 October 2026 Export BEAM’s income statement to Excel — free account

Beam Therapeutics Inc.

Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024. In the quarter to June 2026, revenue fell 94.2%, EPS fell 18.0% and free cash flow grew 13.9%, each against the same quarter a year earlier.

23.47 1.26 −5.10%

Follow BEAM

Alert me

Market cap: $2.6B
P/E: 0.0×
Fwd P/E: −6.7×
Dividend yield: —
F-score: 4/9
Altman Z: 5.41
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 18.55

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	2	5	1	1	5	—	3	1	—	—	1

Insider Ownership 8.72%

Capital & Financial Ratios $m

Market Cap 2,550.00

Revenue 156.04

Net Income (86.52)

Free Cash Flow (372.77)

Net Debt (1,052.67)

Current Ratio 14.57

Debt/Equity 0.09

P/E ratio 0.00

Fwd P/E (6.70)

P/S ratio 15.69

P/B ratio 2.29

Past 5Y EPS Growth —

This Y EPS Growth (447.29%)

Next Y EPS Growth (7.96%)

Next Y revenue growth (65.24%)

Next 5Y EPS Growth (1.61%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 15.80%

10-year low 10-year high

P/B against its own 10 years 20.78%

10-year low 10-year high

EV/Sales against its own 10 years 19.44%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,190	851	1,245	1,153
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	1,211	878	1,269	1,179

	2023	2024	2025	Q'26
Payables	2	4	10	13
ST’ Debt	—	—	—	—
Other	11	8	10	12
	206	182	97	81

Compound Annual Growth %

	10y	5y	3y
Sales	—	466.27%	31.88%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	38.21%	19.07%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	32	0	—	—	—
’25	7	8	10	114	140
’24	7	12	14	30	64
’23	24	20	17	316	378
’22	8	17	16	20	61
’21	0	0	1	51	52
’20	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(129)	(66)	—	—	—
’25	(104)	(76)	(81)	(83)	(345)
’24	(100)	(83)	(88)	(76)	(347)
’23	(110)	(85)	(90)	135	(149)
’22	218	(52)	(74)	(69)	23
’21	(39)	(33)	3	2	(66)
’20	(27)	(23)	(21)	(24)	(96)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(131)	(69)	—	—	—
’25	(107)	(80)	(86)	(87)	(360)
’24	(102)	(85)	(90)	(79)	(356)
’23	(116)	(101)	(98)	131	(183)
’22	211	(74)	(86)	(77)	(26)
’21	(50)	(49)	(3)	(12)	(113)
’20	(30)	(25)	(24)	(32)	(112)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.91)	(1.18)	—	—	—
’25	(1.24)	(1.00)	(1.10)	2.33	(0.81)
’24	(1.21)	(1.11)	(1.17)	(1.09)	(4.58)
’23	(1.33)	(1.08)	(1.22)	1.73	(1.72)
’22	(1.01)	(1.02)	(1.56)	(0.54)	(4.13)
’21	(3.35)	(1.23)	(0.42)	(0.95)	(5.77)
’20	(1.03)	(0.69)	(0.69)	(1.69)	(4.19)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	13.00	56.34	27.77	16.95	20.84	13.53	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	100.65	138.52	82.62	50.74	49.50	35.25
People
People	Employees	—	—	112	118	181	341	507	436	483	511
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.15	0.12	0.87	0.13	0.27
Income, $m
Income, $m	Revenue	—	—	—	0	0	52	61	378	64	140
	Gross margin, %	—	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	(8)	(117)	(78)	(195)	(371)	(260)	(131)	(377)	(80)
	EBT margin, %	—	0.00	0.00	(435,144.44)	(810,800.00)	(714.91)	(427.08)	(34.73)	(593.06)	(57.24)
	Net income	—	0	(117)	(78)	(195)	(371)	(289)	(133)	(377)	(80)
	Depreciation	—	0	1	3	5	7	5	(10)	(1)	6
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.00	0.81	0.87	4.90	0.77	1.41
	Earnings	—	(0.19)	(40.34)	(14.05)	(4.19)	(5.77)	(4.13)	(1.72)	(4.58)	(0.81)
	Cash flow	—	(0.05)	(7.01)	(11.11)	(2.05)	(1.03)	0.32	(1.93)	(4.22)	(3.49)
	Capex	—	0.00	(4.53)	(1.93)	(0.35)	(0.73)	(0.70)	(0.44)	(0.11)	(0.15)
	Free cash flow	—	(0.05)	(11.55)	(13.04)	(2.40)	(1.76)	(0.38)	(2.37)	(4.33)	(3.64)
	Book value	—	(0.08)	(40.57)	(31.04)	5.25	12.87	10.48	12.72	8.91	12.52
	Shares, m	—	50	3	6	47	64	70	77	82	99
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	0.00	158,970.77	98.73	42.89	5.60	32.14	19.62
	P/B	—	—	—	0.00	15.54	6.19	3.56	2.16	2.78	2.21
	EV/Sales	—	—	—	0.00	150,692.81	82.76	27.98	2.87	21.28	11.86
	EV/FCF	—	—	—	(0.65)	(32.26)	(37.94)	(64.52)	(5.94)	(3.79)	(4.60)
Cash, $m
Cash, $m	Operating cash flow	—	(3)	(20)	(72)	(96)	(66)	23	(149)	(347)	(345)
	Capex	—	0	(13)	(13)	(16)	(47)	(49)	(34)	(9)	(15)
	Free cash flow	—	(3)	(33)	(85)	(112)	(113)	(26)	(183)	(356)	(360)
Balance, $m
Balance, $m	Working capital	—	(5)	123	65	206	1,060	869	1,005	696	1,172
	Total debt	—	1	—	32	107	148	182	—	—	—
	Net debt	—	(1)	(146)	(92)	(300)	(966)	(1,078)	(1,190)	(851)	(1,245)
	Shareholders’ equity	—	(4)	(117)	(201)	246	827	733	981	734	1,238
Returns, %
Returns, %	ROA	—	(11.46)	(139.80)	(56.35)	(64.45)	(38.49)	(20.53)	(9.46)	(29.39)	(6.19)
	ROIC	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	15.38	184.70	57.17	(881.16)	(69.13)	(37.06)	(15.46)	(43.94)	(8.11)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DYN Dyne Therapeutics, Inc.	$2.9B	— (loss-making)	—	—	n/m	−39.08% (below 0%: shrinking)	0.00%	0.00%	Compare
NRIX Nurix Therapeutics, Inc.	$2.7B	9.7×	— (loss-making)	+8,426.27% (above 0%: growing)	n/m	+1,122.10% (above 0%: growing)	100.00%	83.12%	Compare
ZLAB Zai Lab Limited Unsponsored ADR	$2.7B	— (loss-making)	— (loss-making)	−3.33% (below 0%: shrinking)	n/m	−84.42% (below 0%: shrinking)	54.70%	(71.95%)	Compare
PGEN Precigen, Inc.	$2.6B	— (loss-making)	— (loss-making)	+6,322.66% (above 0%: growing)	n/m	+8.73% (above 0%: growing)	94.90%	41.18%	Compare
BEAM Beam Therapeutics Inc.	$2.6B	— (loss-making)	— (loss-making)	−94.21% (below 0%: shrinking)	n/m	+13.92% (above 0%: growing)	100.00%	(25,827.14%)
NAMS NewAmsterdam Pharma Company N.V.	$2.5B	— (loss-making)	— (loss-making)	−80.67% (below 0%: shrinking)	n/m	−4.07% (below 0%: shrinking)	100.00%	(1,752.61%)	Compare
MBX MBX Biosciences, Inc.	$2.4B	— (loss-making)	—	—	n/m	−29.67% (below 0%: shrinking)	—	0.00%	Compare
ADMA ADMA Biologics Inc	$2.4B	14.8×	9.5×	+1.98% (above 0%: growing)	+21.43% (above 0%: growing)	+19.72% (above 0%: growing)	69.36%	42.16%	Compare
SLS SELLAS Life Sciences Group, Inc.	$2.3B	— (loss-making)	— (loss-making)	−57.10% (below 0%: shrinking)	n/m	−3.52% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$2.5B	—	—	−0.68%	—	−3.79%	69.36%	0.00%

All 614 Biotechnology stocks →

Beam Therapeutics Inc. (BEAM) key facts

Strength: Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
Beam Therapeutics Inc. (BEAM) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, BEAM traded at $23.47, a market capitalization of $2.6 billion.
Return on equity was −8.11% and debt-to-equity 0.09.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 5.41 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.